Monthly
US$200
Billed every month
Ticagrelor Tablets(替格瑞洛片)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 6 applicationsNo longer listed under review: 2 applicationsSupplement delivery: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders34View records ↓
Under-review filings10View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers59View records ↓
API companies with A status41View records ↓
Chemical-drug catalogue
Loaded records: 34 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 32 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 浙江京新药业股份有限公司 | 浙江京新药业股份有限公司 | 国药准字H20255443 | 2025/09/09 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安若维他药业泰州有限公司 | 安若维他药业泰州有限公司 | 国药准字H20255435 | 2025/09/09 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东凤凰制药股份有限公司 | 山东凤凰制药股份有限公司 | 国药准字H20247182 | 2024/08/05 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江诺得药业有限公司 | 浙江诺得药业有限公司 | 国药准字H20243404 | 2024/03/29 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江诺得药业有限公司 | 浙江诺得药业有限公司 | 国药准字H20243403 | 2024/03/29 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南恒生制药股份有限公司 | 湖南恒生制药股份有限公司 | 国药准字H20233641 | 2023/06/07 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东凤凰制药股份有限公司 | 山东凤凰制药股份有限公司 | 国药准字H20233546 | 2023/05/12 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山西德元堂药业有限公司 | 山西德元堂药业有限公司 | 国药准字H20233528 | 2023/05/12 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山西德元堂药业有限公司 | 山西德元堂药业有限公司 | 国药准字H20233529 | 2023/05/12 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南华纳大药厂股份有限公司 | 湖南华纳大药厂股份有限公司 | 国药准字H20233158 | 2023/02/14 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 常州制药厂有限公司 | 常州制药厂有限公司 | 国药准字H20223502 | 2022/07/07 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 常州制药厂有限公司 | 常州制药厂有限公司 | 国药准字H20223503 | 2022/07/07 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华润双鹤药业股份有限公司 | 华润双鹤药业股份有限公司 | 国药准字H20223190 | 2022/03/29 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都百裕制药股份有限公司 | 成都百裕制药股份有限公司 | 国药准字H20223117 | 2022/03/08 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江昂利康制药股份有限公司 | 浙江昂利康制药股份有限公司 | 国药准字H20223100 | 2022/03/01 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 扬子江药业集团广州海瑞药业有限公司 | 扬子江药业集团广州海瑞药业有限公司 | 国药准字H20227019 | 2022/02/21 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东鲁抗医药股份有限公司 | 山东鲁抗医药股份有限公司 | 国药准字H20213989 | 2021/12/31 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京四环制药有限公司 | 北京四环制药有限公司 | 国药准字H20213970 | 2021/12/31 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京四环制药有限公司 | 北京四环制药有限公司 | 国药准字H20213971 | 2021/12/31 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都倍特药业股份有限公司 | 成都倍特药业股份有限公司 | 国药准字H20213928 | 2021/12/08 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都倍特药业股份有限公司 | 成都倍特药业股份有限公司 | 国药准字H20213929 | 2021/12/08 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东罗欣药业集团股份有限公司 | 山东罗欣药业集团股份有限公司 | 国药准字H20217109 | 2021/11/09 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州特瑞药业有限公司 | 苏州特瑞药业有限公司 | 国药准字H20213419 | 2021/05/26 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 苏州特瑞药业有限公司 | 苏州特瑞药业有限公司 | 国药准字H20213420 | 2021/05/26 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南千金湘江药业股份有限公司 | 湖南千金湘江药业股份有限公司 | 国药准字H20213354 | 2021/05/11 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海口市制药厂有限公司 | 海口市制药厂有限公司 | 国药准字H20213227 | 2021/03/30 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京一心和医药科技有限公司 | 南京海辰药业股份有限公司 | 国药准字H20213179 | 2021/03/16 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京一心和医药科技有限公司 | 南京海辰药业股份有限公司 | 国药准字H20213178 | 2021/03/16 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 乐普药业股份有限公司 | 乐普药业股份有限公司 | 国药准字H20213167 | 2021/03/09 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 乐普药业股份有限公司 | 乐普药业股份有限公司 | 国药准字H20213168 | 2021/03/09 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京福元医药股份有限公司 | 北京福元医药股份有限公司 | 国药准字H20213086 | 2021/01/30 | 90mg | Not stated by source | CDE |
| 山东罗欣药业集团股份有限公司 | 山东罗欣药业集团股份有限公司 | 国药准字H20213073 | 2021/01/30 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海思科制药（眉山）有限公司 | 海思科制药（眉山）有限公司 | 国药准字H20213046 | 2021/01/27 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海思科制药（眉山）有限公司 | 海思科制药（眉山）有限公司 | 国药准字H20213045 | 2021/01/27 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏万邦生化医药集团有限责任公司 | 江苏万邦生化医药集团有限责任公司 | 国药准字H20213028 | 2021/01/19 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药集团欧意药业有限公司 | 石药集团欧意药业有限公司 | 国药准字H20205031 | — | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京正大天晴制药有限公司 | 南京正大天晴制药有限公司 | 国药准字H20205020 | — | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京百奥药业有限责任公司 | 南京柯菲平盛辉制药有限公司 | 国药准字H20203737 | 2020/12/29 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京百奥药业有限责任公司 | 南京柯菲平盛辉制药有限公司 | 国药准字H20203744 | 2020/12/29 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东东阳光药业有限公司 | 广东东阳光药业有限公司 | 国药准字H20203575 | 2020/11/10 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东东阳光药业有限公司 | 广东东阳光药业有限公司 | 国药准字H20203574 | 2020/11/10 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江海正药业股份有限公司 | 浙江海正药业股份有限公司 | 国药准字H20203436 | 2020/08/17 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江海正药业股份有限公司 | 浙江海正药业股份有限公司 | 国药准字H20203435 | 2020/08/17 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 扬子江药业集团广州海瑞药业有限公司 | 扬子江药业集团广州海瑞药业有限公司 | 国药准字H20193366 | 2019/12/16 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 正大天晴药业集团股份有限公司 | 正大天晴药业集团股份有限公司 | 国药准字H20193371 | 2019/12/16 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 南京优科制药有限公司 | 国药准字H20193343 | 2019/11/28 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海汇伦江苏药业有限公司 | 上海汇伦江苏药业有限公司 | 国药准字H20193252 | 2019/09/05 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京正大天晴制药有限公司 | 南京正大天晴制药有限公司 | 国药准字H20193177 | 2019/06/24 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 石药集团欧意药业有限公司 | 国药准字H20193166 | 2019/06/06 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 深圳信立泰药业股份有限公司 | 深圳信立泰药业股份有限公司 | 国药准字H20184165 | 2018/11/30 | 60mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 深圳信立泰药业股份有限公司 | 深圳信立泰药业股份有限公司 | 国药准字H20183320 | 2018/07/31 | 90mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| AstraZeneca AB | Astrazeneca AB | H20171037 | 2017/06/27 | 60mg | Imported originator drug (进口原研药品) | CDE |
| AstraZeneca AB | Astrazeneca AB | H20171079 | 2012/11/22 | 90mg | Imported originator drug (进口原研药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 59 distinct approval numbers and 36 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京四环制药有限公司 | 国药准字H20213970 | 60mg | Category B (乙) | XB01ACT157A001010100153 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20213086 | 90mg | Category B (乙) | XB01ACT157A001010100177 | NHSA |
| 深圳信立泰药业股份有限公司 | 国药准字H20184165 | 60mg | Category B (乙) | XB01ACT157A001010100553 | NHSA |
| 扬子江药业集团广州海瑞药业有限公司 | 国药准字H20193366 | 90mg | Category B (乙) | XB01ACT157A001010100568 | NHSA |
| AstraZeneca AB | 国药准字J20171077 | 90mg | Category B (乙) | XB01ACT157A001010101359 | NHSA |
| 常州制药厂有限公司 | 国药准字H20223502 | 60mg | Category B (乙) | XB01ACT157A001010101397 | NHSA |
| 正大天晴药业集团股份有限公司 | 国药准字H20193371 | 90mg | Category B (乙) | XB01ACT157A001010101523 | NHSA |
| 南京一心和医药科技有限公司 | 国药准字H20213178 | 60mg | Category B (乙) | XB01ACT157A001010101563 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20193177 | 90mg | Category B (乙) | XB01ACT157A001010101606 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20213028 | 90mg | Category B (乙) | XB01ACT157A001010101729 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20213928 | 60mg | Category B (乙) | XB01ACT157A001010102013 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20193166 | 90mg | Category B (乙) | XB01ACT157A001010102770 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001010102877 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20213168 | 60mg | Category B (乙) | XB01ACT157A001010103094 | NHSA |
| 山东凤凰制药股份有限公司 | 国药准字H20233546 | 90mg | Category B (乙) | XB01ACT157A001010104085 | NHSA |
| 山东罗欣药业集团股份有限公司 | 国药准字H20213073 | 90mg | Category B (乙) | XB01ACT157A001010104141 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20223100 | 90mg | Category B (乙) | XB01ACT157A001010104606 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20203435 | 60mg | Category B (乙) | XB01ACT157A001010104641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20255442 | 60mg | Category B (乙) | XB01ACT157A001010104658 | NHSA |
| 湖南恒生制药股份有限公司 | 国药准字H20233641 | 90mg | Category B (乙) | XB01ACT157A001010104900 | NHSA |
| 湖南华纳大药厂股份有限公司 | 国药准字H20233158 | 90mg | Category B (乙) | XB01ACT157A001010104929 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213354 | 90mg | Category B (乙) | XB01ACT157A001010104960 | NHSA |
| 海口市制药厂有限公司 | 国药准字H20213227 | 90mg | Category B (乙) | XB01ACT157A001010105758 | NHSA |
| 四川宏明博思药业有限公司 | 国药准字H20223117 | 90mg | Category B (乙) | XB01ACT157A001010106725 | NHSA |
| 宜昌东阳光长江药业股份有限公司 | 国药准字H20203574 | 60mg | Category B (乙) | XB01ACT157A001010106988 | NHSA |
| 北京百奥药业有限责任公司 | 国药准字H20203744 | 60mg | Category B (乙) | XB01ACT157A001010109751 | NHSA |
| 上海汇伦江苏药业有限公司 | 国药准字H20193252 | 90mg | Category B (乙) | XB01ACT157A001010110104 | NHSA |
| 山东简道制药有限公司 | 国药准字H20213419 | 60mg | Category B (乙) | XB01ACT157A001010110121 | NHSA |
| AstraZeneca AB | H20171037 | 60mg | Category B (乙) | XB01ACT157A001010179096 | NHSA |
| 南京优科制药有限公司 | 国药准字H20193343 | 90mg | Category B (乙) | XB01ACT157A001010180542 | NHSA |
| 华润双鹤药业股份有限公司 | 国药准字H20223190 | 90mg | Category B (乙) | XB01ACT157A001010181661 | NHSA |
| 海思科制药(眉山)有限公司 | 国药准字H20213046 | 60mg | Category B (乙) | XB01ACT157A001010182860 | NHSA |
| 山东鲁抗医药股份有限公司 | 国药准字H20213989 | 90mg | Category B (乙) | XB01ACT157A001010183198 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001010183521 | NHSA |
| 安若维他药业泰州有限公司 | 国药准字H20255435 | 60mg | Category B (乙) | XB01ACT157A001010183769 | NHSA |
| 北京四环制药有限公司 | 国药准字H20213970 | 60mg | Category B (乙) | XB01ACT157A001010200153 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20213086 | 90mg | Category B (乙) | XB01ACT157A001010200177 | NHSA |
| 扬子江药业集团广州海瑞药业有限公司 | 国药准字H20193366 | 90mg | Category B (乙) | XB01ACT157A001010200568 | NHSA |
| AstraZeneca AB | 国药准字J20171077 | 90mg | Category B (乙) | XB01ACT157A001010201359 | NHSA |
| 常州制药厂有限公司 | 国药准字H20223502 | 60mg | Category B (乙) | XB01ACT157A001010201397 | NHSA |
| 正大天晴药业集团股份有限公司 | 国药准字H20193371 | 90mg | Category B (乙) | XB01ACT157A001010201523 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20193177 | 90mg | Category B (乙) | XB01ACT157A001010201606 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20213028 | 90mg | Category B (乙) | XB01ACT157A001010201729 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20193166 | 90mg | Category B (乙) | XB01ACT157A001010202770 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001010202877 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20213168 | 60mg | Category B (乙) | XB01ACT157A001010203094 | NHSA |
| 山东凤凰制药股份有限公司 | 国药准字H20233546 | 90mg | Category B (乙) | XB01ACT157A001010204085 | NHSA |
| 山东罗欣药业集团股份有限公司 | 国药准字H20213073 | 90mg | Category B (乙) | XB01ACT157A001010204141 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20223100 | 90mg | Category B (乙) | XB01ACT157A001010204606 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20203435 | 60mg | Category B (乙) | XB01ACT157A001010204641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20255442 | 60mg | Category B (乙) | XB01ACT157A001010204658 | NHSA |
| 湖南恒生制药股份有限公司 | 国药准字H20233641 | 90mg | Category B (乙) | XB01ACT157A001010204900 | NHSA |
| 湖南华纳大药厂股份有限公司 | 国药准字H20233158 | 90mg | Category B (乙) | XB01ACT157A001010204929 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213354 | 90mg | Category B (乙) | XB01ACT157A001010204960 | NHSA |
| 海口市制药厂有限公司 | 国药准字H20213227 | 90mg | Category B (乙) | XB01ACT157A001010205758 | NHSA |
| 四川宏明博思药业有限公司 | 国药准字H20223117 | 90mg | Category B (乙) | XB01ACT157A001010206725 | NHSA |
| 宜昌东阳光长江药业股份有限公司 | 国药准字H20203574 | 60mg | Category B (乙) | XB01ACT157A001010206988 | NHSA |
| 上海汇伦江苏药业有限公司 | 国药准字H20193252 | 90mg | Category B (乙) | XB01ACT157A001010210104 | NHSA |
| 山东简道制药有限公司 | 国药准字H20213419 | 60mg | Category B (乙) | XB01ACT157A001010210121 | NHSA |
| AstraZeneca AB | H20171037 | 60mg | Category B (乙) | XB01ACT157A001010279096 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001010283521 | NHSA |
| 安若维他药业泰州有限公司 | 国药准字H20255435 | 60mg | Category B (乙) | XB01ACT157A001010283769 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20213086 | 90mg | Category B (乙) | XB01ACT157A001010300177 | NHSA |
| AstraZeneca AB | 国药准字J20171077 | 90mg | Category B (乙) | XB01ACT157A001010301359 | NHSA |
| 常州制药厂有限公司 | 国药准字H20223502 | 60mg | Category B (乙) | XB01ACT157A001010301397 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20193177 | 90mg | Category B (乙) | XB01ACT157A001010301606 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20213028 | 90mg | Category B (乙) | XB01ACT157A001010301729 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20193166 | 90mg | Category B (乙) | XB01ACT157A001010302770 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001010302877 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20213168 | 60mg | Category B (乙) | XB01ACT157A001010303094 | NHSA |
| 山东凤凰制药股份有限公司 | 国药准字H20233546 | 90mg | Category B (乙) | XB01ACT157A001010304085 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20223100 | 90mg | Category B (乙) | XB01ACT157A001010304606 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20203435 | 60mg | Category B (乙) | XB01ACT157A001010304641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20255442 | 60mg | Category B (乙) | XB01ACT157A001010304658 | NHSA |
| 湖南恒生制药股份有限公司 | 国药准字H20233641 | 90mg | Category B (乙) | XB01ACT157A001010304900 | NHSA |
| 湖南华纳大药厂股份有限公司 | 国药准字H20233158 | 90mg | Category B (乙) | XB01ACT157A001010304929 | NHSA |
| 湖南千金湘江药业股份有限公司 | 国药准字H20213354 | 90mg | Category B (乙) | XB01ACT157A001010304960 | NHSA |
| 四川宏明博思药业有限公司 | 国药准字H20223117 | 90mg | Category B (乙) | XB01ACT157A001010306725 | NHSA |
| AstraZeneca AB | H20171037 | 60mg | Category B (乙) | XB01ACT157A001010379096 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001010383521 | NHSA |
| 安若维他药业泰州有限公司 | 国药准字H20255435 | 60mg | Category B (乙) | XB01ACT157A001010383769 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20213086 | 90mg | Category B (乙) | XB01ACT157A001010400177 | NHSA |
| 常州制药厂有限公司 | 国药准字H20223502 | 60mg | Category B (乙) | XB01ACT157A001010401397 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20193177 | 90mg | Category B (乙) | XB01ACT157A001010401606 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20213028 | 90mg | Category B (乙) | XB01ACT157A001010401729 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20193166 | 90mg | Category B (乙) | XB01ACT157A001010402770 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001010402877 | NHSA |
| 山东凤凰制药股份有限公司 | 国药准字H20233546 | 90mg | Category B (乙) | XB01ACT157A001010404085 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20223100 | 90mg | Category B (乙) | XB01ACT157A001010404606 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20255442 | 60mg | Category B (乙) | XB01ACT157A001010404658 | NHSA |
| 湖南华纳大药厂股份有限公司 | 国药准字H20233158 | 90mg | Category B (乙) | XB01ACT157A001010404929 | NHSA |
| 四川宏明博思药业有限公司 | 国药准字H20223117 | 90mg | Category B (乙) | XB01ACT157A001010406725 | NHSA |
| 阿斯利康制药有限公司 | 国药准字H20217034 | 60mg | Category B (乙) | XB01ACT157A001010479096 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001010483521 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20213086 | 90mg | Category B (乙) | XB01ACT157A001010500177 | NHSA |
| 常州制药厂有限公司 | 国药准字H20223502 | 60mg | Category B (乙) | XB01ACT157A001010501397 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20193166 | 90mg | Category B (乙) | XB01ACT157A001010502770 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001010502877 | NHSA |
| 山东凤凰制药股份有限公司 | 国药准字H20233546 | 90mg | Category B (乙) | XB01ACT157A001010504085 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20223100 | 90mg | Category B (乙) | XB01ACT157A001010504606 | NHSA |
| 四川宏明博思药业有限公司 | 国药准字H20223117 | 90mg | Category B (乙) | XB01ACT157A001010506725 | NHSA |
| 阿斯利康制药有限公司 | 国药准字H20217034 | 60mg | Category B (乙) | XB01ACT157A001010579096 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001010583521 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20213086 | 90mg | Category B (乙) | XB01ACT157A001010600177 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001010602877 | NHSA |
| 浙江昂利康制药股份有限公司 | 国药准字H20223100 | 90mg | Category B (乙) | XB01ACT157A001010604606 | NHSA |
| 阿斯利康制药有限公司 | 国药准字H20217034 | 60mg | Category B (乙) | XB01ACT157A001010679096 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001010683521 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20213086 | 90mg | Category B (乙) | XB01ACT157A001010700177 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001010702877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001010783521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001010802877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001010883521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001010902877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001010983521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001011002877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001011083521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001011102877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001011183521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001011202877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001011283521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001011302877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001011383521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001011402877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001011483521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001011502877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001011583521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001011602877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001011683521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001011702877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001011783521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001011802877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001011883521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001011902877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001011983521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233528 | 60mg | Category B (乙) | XB01ACT157A001012002877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001012083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001012183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001012283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001012383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001012483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243403 | 60mg | Category B (乙) | XB01ACT157A001012583521 | NHSA |
| 北京四环制药有限公司 | 国药准字H20213971 | 90mg | Category B (乙) | XB01ACT157A001020100153 | NHSA |
| 深圳信立泰药业股份有限公司 | 国药准字H20183320 | 90mg | Category B (乙) | XB01ACT157A001020100553 | NHSA |
| 扬子江药业集团广州海瑞药业有限公司 | 国药准字H20227019 | 60mg | Category B (乙) | XB01ACT157A001020100568 | NHSA |
| 常州制药厂有限公司 | 国药准字H20223503 | 90mg | Category B (乙) | XB01ACT157A001020101397 | NHSA |
| 南京一心和医药科技有限公司 | 国药准字H20213179 | 90mg | Category B (乙) | XB01ACT157A001020101563 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20205020 | 60mg | Category B (乙) | XB01ACT157A001020101606 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20213028 | 90mg | Category B (乙) | XB01ACT157A001020101729 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20213929 | 90mg | Category B (乙) | XB01ACT157A001020102013 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20205031 | 60mg | Category B (乙) | XB01ACT157A001020102770 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001020102877 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20213167 | 90mg | Category B (乙) | XB01ACT157A001020103094 | NHSA |
| 山东罗欣药业集团股份有限公司 | 国药准字H20217109 | 60mg | Category B (乙) | XB01ACT157A001020104141 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20203436 | 90mg | Category B (乙) | XB01ACT157A001020104641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20255443 | 90mg | Category B (乙) | XB01ACT157A001020104658 | NHSA |
| 宜昌东阳光长江药业股份有限公司 | 国药准字H20203575 | 90mg | Category B (乙) | XB01ACT157A001020106988 | NHSA |
| 成都迪康药业股份有限公司 | 国药准字H20203737 | 90mg | Category B (乙) | XB01ACT157A001020109751 | NHSA |
| 上海汇伦江苏药业有限公司 | 国药准字H20205005 | 60mg | Category B (乙) | XB01ACT157A001020110104 | NHSA |
| 山东简道制药有限公司 | 国药准字H20213420 | 90mg | Category B (乙) | XB01ACT157A001020110121 | NHSA |
| 阿斯利康制药有限公司 | H20171079 | 90mg | Category B (乙) | XB01ACT157A001020179096 | NHSA |
| 海思科制药(眉山)有限公司 | 国药准字H20213045 | 90mg | Category B (乙) | XB01ACT157A001020182860 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001020183521 | NHSA |
| 安若维他药业泰州有限公司 | 国药准字H20255436 | 90mg | Category B (乙) | XB01ACT157A001020183769 | NHSA |
| 北京四环制药有限公司 | 国药准字H20213971 | 90mg | Category B (乙) | XB01ACT157A001020200153 | NHSA |
| 常州制药厂有限公司 | 国药准字H20223503 | 90mg | Category B (乙) | XB01ACT157A001020201397 | NHSA |
| 南京一心和医药科技有限公司 | 国药准字H20213179 | 90mg | Category B (乙) | XB01ACT157A001020201563 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20205020 | 60mg | Category B (乙) | XB01ACT157A001020201606 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001020202877 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20213167 | 90mg | Category B (乙) | XB01ACT157A001020203094 | NHSA |
| 山东罗欣药业集团股份有限公司 | 国药准字H20217109 | 60mg | Category B (乙) | XB01ACT157A001020204141 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20203436 | 90mg | Category B (乙) | XB01ACT157A001020204641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20255443 | 90mg | Category B (乙) | XB01ACT157A001020204658 | NHSA |
| 成都迪康药业股份有限公司 | 国药准字H20203737 | 90mg | Category B (乙) | XB01ACT157A001020209751 | NHSA |
| 山东简道制药有限公司 | 国药准字H20213420 | 90mg | Category B (乙) | XB01ACT157A001020210121 | NHSA |
| 阿斯利康制药有限公司 | H20171079 | 90mg | Category B (乙) | XB01ACT157A001020279096 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001020283521 | NHSA |
| 安若维他药业泰州有限公司 | 国药准字H20255436 | 90mg | Category B (乙) | XB01ACT157A001020283769 | NHSA |
| 北京四环制药有限公司 | 国药准字H20213971 | 90mg | Category B (乙) | XB01ACT157A001020300153 | NHSA |
| 常州制药厂有限公司 | 国药准字H20223503 | 90mg | Category B (乙) | XB01ACT157A001020301397 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20205020 | 60mg | Category B (乙) | XB01ACT157A001020301606 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001020302877 | NHSA |
| 乐普药业股份有限公司 | 国药准字H20213167 | 90mg | Category B (乙) | XB01ACT157A001020303094 | NHSA |
| 山东罗欣药业集团股份有限公司 | 国药准字H20217109 | 60mg | Category B (乙) | XB01ACT157A001020304141 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20203436 | 90mg | Category B (乙) | XB01ACT157A001020304641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20255443 | 90mg | Category B (乙) | XB01ACT157A001020304658 | NHSA |
| 成都迪康药业股份有限公司 | 国药准字H20203737 | 90mg | Category B (乙) | XB01ACT157A001020309751 | NHSA |
| 山东简道制药有限公司 | 国药准字H20213420 | 90mg | Category B (乙) | XB01ACT157A001020310121 | NHSA |
| 阿斯利康制药有限公司 | H20171079 | 90mg | Category B (乙) | XB01ACT157A001020379096 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001020383521 | NHSA |
| 安若维他药业泰州有限公司 | 国药准字H20255436 | 90mg | Category B (乙) | XB01ACT157A001020383769 | NHSA |
| 常州制药厂有限公司 | 国药准字H20223503 | 90mg | Category B (乙) | XB01ACT157A001020401397 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001020402877 | NHSA |
| 山东罗欣药业集团股份有限公司 | 国药准字H20217109 | 60mg | Category B (乙) | XB01ACT157A001020404141 | NHSA |
| 浙江海正药业股份有限公司 | 国药准字H20203436 | 90mg | Category B (乙) | XB01ACT157A001020404641 | NHSA |
| 浙江京新药业股份有限公司 | 国药准字H20255443 | 90mg | Category B (乙) | XB01ACT157A001020404658 | NHSA |
| 成都迪康药业股份有限公司 | 国药准字H20203737 | 90mg | Category B (乙) | XB01ACT157A001020409751 | NHSA |
| 阿斯利康制药有限公司 | 国药准字H20217033 | 90mg | Category B (乙) | XB01ACT157A001020479096 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001020483521 | NHSA |
| 常州制药厂有限公司 | 国药准字H20223503 | 90mg | Category B (乙) | XB01ACT157A001020501397 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001020502877 | NHSA |
| 阿斯利康制药有限公司 | 国药准字H20217033 | 90mg | Category B (乙) | XB01ACT157A001020579096 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001020583521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001020602877 | NHSA |
| 阿斯利康制药有限公司 | 国药准字H20217033 | 90mg | Category B (乙) | XB01ACT157A001020679096 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001020683521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001020702877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001020783521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001020802877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001020883521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001020902877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001020983521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001021002877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001021083521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001021102877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001021183521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001021202877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001021283521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001021302877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001021383521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001021402877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001021483521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001021502877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001021583521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001021602877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001021683521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001021702877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001021783521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001021802877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001021883521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001021902877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001021983521 | NHSA |
| 山西德元堂药业有限公司 | 国药准字H20233529 | 90mg | Category B (乙) | XB01ACT157A001022002877 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001022083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001022183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001022283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001022383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001022483521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001022583521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001022683521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001022783521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001022883521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001022983521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001023083521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001023183521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001023283521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001023383521 | NHSA |
| 浙江诺得药业有限公司 | 国药准字H20243404 | 90mg | Category B (乙) | XB01ACT157A001023483521 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20217080 | 60mg | Category B (乙) | XB01ACT157A001030101729 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 10 filings and 7 distinct first applicants.
Generic 7 · Supplement 3
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 广东彼迪药业有限公司 | CYHS2602489 | Generic | 2026/10/10 | Not stated by source | CDE |
| 广东彼迪药业有限公司 | CYHS2602488 | Generic | 2026/10/10 | Not stated by source | CDE |
| 多多药业有限公司 | CYHS2602214 | Generic | 2026/09/07 | Not stated by source | CDE |
| 多多药业有限公司 | CYHS2602213 | Generic | 2026/09/07 | Not stated by source | CDE |
| AstraZeneca AB | JYHB2600465 | Supplement | 2026/08/13 | Not stated by source | CDE |
| AstraZeneca AB | JYHB2600464 | Supplement | 2026/08/13 | Not stated by source | CDE |
| 浙江诺得药业有限公司 | CYHB2600840 | Supplement | 2026/04/28 | Not stated by source | CDE |
| 江苏飞马药业有限公司;北京莱瑞森医药科技有限公司 | CYHS1900906 | Generic | 2020/01/09 | Not stated by source | CDE |
| 浙江江北药业有限公司 | CYHS2504240 | Generic | 2025/12/10 | Not stated by source | CDE |
| 华中药业股份有限公司 | CYHS2503761 | Generic | 2025/10/22 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 4 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 广东彼迪药业有限公司 | CYHS2602489 | Generic | 2026/10/10 | Not stated by source | CDE |
| 广东彼迪药业有限公司 | CYHS2602488 | Generic | 2026/10/10 | Not stated by source | CDE |
| 多多药业有限公司 | CYHS2602214 | Generic | 2026/09/07 | Not stated by source | CDE |
| 多多药业有限公司 | CYHS2602213 | Generic | 2026/09/07 | Not stated by source | CDE |
API registrations
Non-component matches: 41 companies with A status and 5 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 替格瑞洛 | 万洋衡水制药有限公司 | Y20250000568 | I | Exact ingredient | 2025/06/13 | CDE |
| 替格瑞洛 | 华中药业股份有限公司 | Y20240001125 | A | Exact ingredient | 2026/03/12 | CDE |
| 替格瑞洛 | 浙江尚泰生物制药有限公司 | Y20230000999 | A | Exact ingredient | 2026/09/19 | CDE |
| 替格瑞洛 | 浙江江北南海药业有限公司 | Y20230000478 | A | Exact ingredient | 2024/12/31 | CDE |
| 替格瑞洛 | 绍兴京新药业有限公司 | Y20220000924 | A | Exact ingredient | 2024/11/07 | CDE |
| 替格瑞洛 | 天津力生制药股份有限公司 | Y20220000685 | A | Exact ingredient | 2024/02/28 | CDE |
| 替格瑞洛 | 浙江海正药业股份有限公司 | Y20220000387 | A | Exact ingredient | 2023/05/30 | CDE |
| 替格瑞洛 | COHANCE LIFESCIENCES LIMITED | Y20220000030 | A | Exact ingredient | 2025/05/25 | CDE |
| 替格瑞洛 | 江苏永安制药有限公司 | Y20210000078 | A | Exact ingredient | 2022/10/14 | CDE |
| 替格瑞洛 | 山西双雁药业有限公司（原名山西新宝源制药有限公司） | Y20210000171 | A | Exact ingredient | 2023/05/22 | CDE |
| 替格瑞洛 | AstraZeneca AB | Y20210000149 | A | Exact ingredient | 2023/04/06 | CDE |
| 替格瑞洛 | 南通常佑药业科技有限公司 | Y20200001172 | A | Exact ingredient | 2026/07/17 | CDE |
| 替格瑞洛 | Alembic Pharmaceuticals Limited | Y20200001135 | A | Exact ingredient | 2024/01/17 | CDE |
| 替格瑞洛 | 亚宝药业集团股份有限公司 | Y20200000954 | A | Exact ingredient | 2022/11/04 | CDE |
| 替格瑞洛 | 成都百裕制药股份有限公司 | Y20200000686 | A | Exact ingredient | 2026/01/10 | CDE |
| 替格瑞洛 | 双鹤药业（商丘）有限责任公司 | Y20200000694 | A | Exact ingredient | 2026/08/17 | CDE |
| 替格瑞洛 | 四川仁安药业有限责任公司 | Y20200000680 | A | Exact ingredient | 2026/09/21 | CDE |
| 替格瑞洛 | MSN Organics Private Limited | Y20190000851 | I | Exact ingredient | 2020/07/29 | CDE |
| 替格瑞洛 | 湖南华纳大药厂手性药物有限公司 | Y20200000032 | A | Exact ingredient | 2026/06/13 | CDE |
| 替格瑞洛 | 吉林汇康制药有限公司 | Y20200000568 | A | Exact ingredient | 2026/07/27 | CDE |
| 替格瑞洛 | 四川青木制药有限公司 | Y20200000293 | A | Exact ingredient | 2026/07/13 | CDE |
| 替格瑞洛 | 扬子江药业集团江苏海慈生物药业有限公司 | Y20180001779 | A | Exact ingredient | 2024/10/26 | CDE |
| 替格瑞洛 | 泓博智源（开原）药业有限公司 | Y20190021511 | A | Exact ingredient | 2026/09/16 | CDE |
| 替格瑞洛 | 苏州立新制药有限公司 | Y20190000285 | A | Exact ingredient | 2026/03/21 | CDE |
| 替格瑞洛 | 湖南千金湘江药业股份有限公司 | Y20190000663 | A | Exact ingredient | 2026/05/11 | CDE |
| 替格瑞洛 | 浙江乐普药业股份有限公司 | Y20190000753 | A | Exact ingredient | 2026/01/06 | CDE |
| 替格瑞洛 | 山东鲁抗医药股份有限公司 | Y20190000560 | A | Exact ingredient | 2026/09/30 | CDE |
| 替格瑞洛 | 江苏创诺制药有限公司 | Y20180000480 | I | Exact ingredient | 2019/05/22 | CDE |
| 替格瑞洛 | 北京福元医药股份有限公司 | Y20190000257 | A | Exact ingredient | 2025/07/04 | CDE |
| 替格瑞洛 | 武汉武药制药有限公司 | Y20180001594 | I | Exact ingredient | 2019/02/25 | CDE |
| 替格瑞洛 | 山东罗欣药业集团恒欣药业有限公司 | Y20180001354 | A | Exact ingredient | 2025/11/01 | CDE |
| 替格瑞洛 | 江西同和药业股份有限公司 | Y20180000483 | A | Exact ingredient | 2026/04/01 | CDE |
| 替格瑞洛 | 南京一心和医药科技有限公司 | Y20180001056 | A | Exact ingredient | 2023/07/28 | CDE |
| 替格瑞洛 | 宜昌东阳光长江药业股份有限公司 | Y20180001144 | A | Exact ingredient | 2026/08/20 | CDE |
| 替格瑞洛 | 南京柯菲平制药有限公司 | Y20180001054 | A | Exact ingredient | 2026/03/18 | CDE |
| 替格瑞洛 | 四川海思科制药有限公司 | Y20180000956 | A | Exact ingredient | 2025/07/30 | CDE |
| 替格瑞洛 | 四川新开元制药有限公司 | Y20180000632 | I | Exact ingredient | — | CDE |
| 替格瑞洛 | 连云港润众制药有限公司 | Y20180001728 | A | Exact ingredient | 2024/10/01 | CDE |
| 替格瑞洛 | 上海汇伦江苏药业有限公司,上海汇伦江苏药业有限公司 | Y20180001721 | A | Exact ingredient | 2025/06/29 | CDE |
| 替格瑞洛 | 江苏普润生物医药有限公司 | Y20170002354 | A | Exact ingredient | 2026/06/12 | CDE |
| 替格瑞洛 | 徐州万邦金桥制药有限公司 | Y20180000407 | A | Exact ingredient | 2025/11/22 | CDE |
| 替格瑞洛 | 浙江天宇药业股份有限公司 | Y20170002223 | A | Exact ingredient | 2026/02/13 | CDE |
| 替格瑞洛 | 石药集团欧意药业有限公司 | Y20170001631 | A | Exact ingredient | 2026/06/02 | CDE |
| 替格瑞洛 | Dr.Reddy's Laboratories Limited | Y20170001609 | A | Exact ingredient | 2025/02/27 | CDE |
| 替格瑞洛 | 南京优科制药有限公司 | Y20170001578 | A | Exact ingredient | 2024/10/01 | CDE |
| 替格瑞洛 | 惠州信立泰药业有限公司 | Y20170001542 | A | Exact ingredient | 2025/08/09 | CDE |
| 替格瑞洛 | AstraZeneca AB | Y20170001491 | A | Exact ingredient | 2024/09/25 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/07No longer listed under review
阿斯利康制药有限公司
CYHB2601532
Fact date: 2026/11/07 · Site observation date: 2026/11/07
Accepted: 2026/08/11
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/06 (approval no.: —; approval date: 2026/11/05); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 27
NMPA · Table row 27 ↗ View source ↗ -
2026/11/07No longer listed under review
阿斯利康制药有限公司
CYHB2601531
Fact date: 2026/11/07 · Site observation date: 2026/11/07
Accepted: 2026/08/11
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/06 (approval no.: —; approval date: 2026/11/05); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 26
NMPA · Table row 26 ↗ View source ↗ -
2026/11/05Supplement delivery
阿斯利康制药有限公司
CYHB2601532
Fact date: 2026/11/05 · Publication date: 2026/11/06 · Site observation date: 2026/11/06
Supplemental application; excluded from new marketing approvals.
View source · Table row 27 ↗ -
2026/11/05Supplement delivery
阿斯利康制药有限公司
CYHB2601531
Fact date: 2026/11/05 · Publication date: 2026/11/06 · Site observation date: 2026/11/06
Supplemental application; excluded from new marketing approvals.
View source · Table row 26 ↗ -
2026/10/10Accepted
-
2026/10/10Accepted
-
2026/09/07Accepted
-
2026/09/07Accepted
-
2026/08/13Accepted
-
2026/08/13Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Ticagrelor Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy